New pharmacotherapy for the treatment of glaucoma

Emily M. Schehlein, Gary Novack, Alan L. Robin

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations


Introduction: Glaucoma is the second leading cause of blindness in the world and current pharmacotherapies for glaucoma have remained relatively unchanged (with the exception of fixed combinations of previously available medications) since the mid-1990s with the development of prostaglandin analogues. Now, with both new formulations and new classes of medications with novel mechanisms of action, the medical therapy of glaucoma may be heralding a new dawn in medical management. Areas covered: This review outlines new topical therapies for intraocular pressure (IOP) lowering treatment, in addition to new formulations, preservative-free options, and advances in glaucoma medical therapy delivery. We performed a comprehensive search for published studies for glaucoma medical therapy using the electronic database PubMed. A manual search for each therapy or delivery system was also performed. Expert commentary: These advances in glaucoma therapy have the potential to overcome many barriers to glaucoma’s medical care, particularly in terms of adherence. However, both time and research are needed to prove the relative efficacy and safety of these new pharmacotherapies and products, helping us decide their role in the treatment of elevated intraocular pressure. We are hopeful that these new developments in therapy may bring more options for glaucoma medical therapy.

Original languageEnglish (US)
Pages (from-to)1939-1946
Number of pages8
JournalExpert opinion on pharmacotherapy
Issue number18
StatePublished - Dec 12 2017


  • Glaucoma
  • administration
  • drug formulations
  • medical therapy
  • pharmacotherapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology


Dive into the research topics of 'New pharmacotherapy for the treatment of glaucoma'. Together they form a unique fingerprint.

Cite this